Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 4Phase 4 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 5NET 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Octreotide 4Everolimus 4lanreotide 3pasireotide 2Carboplatin 2surufatinib 1lutetium Lu 177 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1arginyllysine 1Surveys and Questionnaires 1Sunitinib 1Somatostatin 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Diazoxide 1Cisplatin 1Cabergoline 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × lanreotide × NET × Clear all
NCT05701241 2024-06-14

SAUNA

University Hospital, Antwerp

Phase 4 Recruiting
270 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT02075606 2019-06-07

CALM-NET

Ipsen

Phase 4 Completed
50 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

NCT03083210 2019-05-20

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Samsung Medical Center

Phase 4 Unknown
28 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡